A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia

NCT02477020 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

164

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: TAK-063 20 mg
DRUG: Placebo

Sponsor

Takeda